Talphera, Inc. Price & Performance (TLPH)

Danaher reported a robust first quarter, with core revenue in its biotechnology segment rising 7% and consumables seeing double-digit growth. The company maintained its full-year guidance, projecting core revenue growth of about 3% and adjusted EPS between $7.60 and $7.75, reflecting confidence despite market uncertainties.12

Talphera, formerly AcelRx, is progressing with Niyad, an anticoagulant for extracorporeal circuits, and LTX-608, targeting inflammatory and viral conditions. The company’s valuation metrics are in line with healthcare peers, and its product pipeline positions it to address critical needs in medically supervised settings.34

Several notable corporate actions have occurred, including reverse splits by Wheeler Real Estate and Jaguar Health, and the delisting of Avenue Therapeutics to OTC. These moves reflect ongoing volatility and strategic repositioning across sectors, impacting shareholder value and market structure as companies adapt to changing conditions.5